Objective. The HIV Prevention Trials Network (HPTN) 065 trial sought to expand HIV screening of emergency department (ED) patients in Bronx, New York, and Washington, D.C. This study assessed the testing costs associated with different expansion processes and compared them with costs of a hypothetical optimized process.
Of the 1.1 million people in the United States living with human immunodeficiency virus (HIV), approximately 14% are unaware of their HIV infection. 1 These individuals are not receiving appropriate medical care and are at a disproportionately high risk of transmitting HIV to their partners, contributing to the approximately 47,500 people who become infected with HIV in the United States each year. 2 The "test and treat" prevention model, which includes routine testing of individuals to detect HIV infection early and links HIVinfected people to antiretroviral therapy immediately upon diagnosis, could play a central role in curbing the HIV epidemic.
In support of this model, the Centers for Disease Control and Prevention (CDC) recommends opt-out HIV screening as part of routine clinical care for adults and adolescents in all health-care settings. 3 Currently, all states except Nebraska have laws that are consistent with CDC's recommendations. 4, 5 Single-center studies have shown that routine HIV testing is feasible in a variety of health-care settings, including emergency departments (EDs). [6] [7] [8] [9] [10] Nevertheless, uptake of these recommendations by health-care providers has been slowed by a lack of perceived HIV risk among ED patients 11 and lack of reimbursement by public and private insurers. 12, 13 In 2013, the U.S. Preventive Services Task Force recommended routine HIV screening for adults with a Grade A recommendation (i.e., there was high certainty that the net benefit was substantial), and, under the Affordable Care Act, private insurers are required to cover tests with this recommendation without copayments from patients. 14 However, the reimbursement amount to providers is not specified, and hospitals may still have difficulty obtaining reimbursement that is separate from negotiated fixed payments for ED visits.
The HIV Prevention Trials Network (HPTN) 065 trial evaluated the feasibility of an enhanced test, linkage to care, plus treat approach for HIV prevention in the United States. 15 One component of this 36-month, community-level trial was for 17 sites located in Bronx, New York, and Washington, D.C.(DC), to attempt universal offers of HIV testing to ED patients and hospital inpatients. This component was conducted in the context of ongoing social mobilization and HIV testing expansion efforts in both communities. Hospital leadership and medical staff members were encouraged to add HIV testing to established laboratory testing order procedures for ED patients (standing orders), to use novel mechanisms to deliver information about HIV testing to patients, and to perform testing with rapid-result laboratory HIV testing platforms that could expand testing volumes when compared with point-of-care (POC) testing and allow detection of acute HIV infections. 16 On average, fewer than 20% of patients in both cities were tested during ED visits, and the percentage of HIV-positive tests exceeded the 0.1% threshold for routine screening, as recommended by CDC. 17 Given the need to address potential reimbursement barriers and minimize the cost of screening, we collected data from four hospitals participating in this component of the trial to determine the cost of expanded POC and laboratory HIV testing in their EDs. We also calculated the hypothetical cost of an optimized ED laboratory HIV testing process.
METHODS

Overview
We conducted interviews and collected cost data from July 2013 through September 2014 from four HPTN 065 participant hospitals in the Bronx and DC that had switched from POC to rapid-result laboratory testing for some or all ED patients. Adults seeking medical services in the ED were offered an HIV test if they met hospital-specific eligibility criteria that included no recent documented HIV test (three or six months, depending on the hospital) and no self-report of HIV infection. Costs are reported in 2013 U.S. dollars and do not include overhead costs (e.g., costs of supervision, administration, space, and utilities). We performed analyses in Microsoft ® Excel ® 2013.
Process flow and time estimates
To document ED HIV testing practices, we conducted in-person interviews at each hospital with laboratory personnel and counselors involved in HIV testing and linkage-to-care processes. Interviews lasted approximately one hour. We also conducted observations to better understand overall ED process flows. To determine times for each step of the process, we asked laboratory personnel and counselors to describe how much time was typically required for each step. We used data on the average number of HIV tests conducted to assign a portion of the time required to run HIV controls for each test. The time estimates excluded downtime (i.e., when testing was not being performed) because we assumed personnel performed other unrelated activities. As a result, estimates might represent a lower bound of actual labor time associated with POC or laboratory testing.
We then synthesized data collected during interviews and observations to map HIV testing process flows and time durations for lower acuity urgent care (fasttrack) ED patients, who generally do not have blood drawn unless they are offered and accept laboratory HIV testing, and for other ED patients who generally require a blood draw for clinical purposes. Three of the hospitals chose to conduct POC HIV testing for fast-track ED patients. We summarized the process steps for each track as follows: provide information about HIV testing, confirm HIV screening eligibility, order HIV test, collect specimen, process HIV test, deliver and document results (nonreactive), deliver and document results (reactive), perform HIV confirmatory testing on-site or off-site, and link to care.
Cost analysis
We used micro-costing methods 18 similar to those in our previous economic analyses of HIV testing in substance abuse treatment programs 19 and in sexually transmitted disease clinics 20 to determine the cost of conducting HIV testing in the four EDs. Where possible, we used national labor costs to compare our findings across institutions. 21 We applied national wage and fringe rates 22 to time estimates for each process step. To calculate the cost of laboratory HIV testing, we obtained the cost of reagents and controls from each hospital and the cost of laboratory equipment from one hospital that used a third-generation HIV assay and one that used a fourth-generation HIV assay. Both assays detect HIV infection earlier than POC tests by using equipment that can produce HIV test results in less than one hour and can perform tests other than HIV. 16 Laboratory equipment costs included service contracts and annualized costs for equipment purchase, assuming straight-line depreciation during a four-year contract term, or annual leasing costs. To assign a portion of the equipment costs to each HIV test, we used data on the number of HIV tests performed and the percentage of HIV tests conducted with the equipment. For confirmatory HIV testing, we used the national rate 23 if the confirmatory test was performed by an outside laboratory, or the hospital's cost if its laboratory conducted the confirmatory test. We used national costs from a survey of health departments for the cost of POC HIV tests. 24 Further details on labor and materials costs are available on request.
Costs are reported as cost per nonreactive HIV test result, cost per reactive HIV test result, and cost per ED visit to conduct HIV testing. We calculated cost per test result by summing the labor and materials costs for each relevant process step. To address potential budget impact, we calculated costs to conduct expanded HIV testing for each hospital and reported them as cost per ED visit. To calculate the cost per ED visit, we summed the labor and materials costs for each relevant process step, weighted by the percentage of ED patients who experienced that process step, and divided by the total number of ED visits. Each hospital provided data on ED admissions and the number of patients testing nonreactive and reactive for the relevant period ending January 2014 (ranging from three to 13 months) when the process flow was in place. In sensitivity analyses, we varied the percentage of ED patients receiving an HIV test and the percentage of tests with a reactive result.
Hypothetical optimized process
To construct a hypothetical optimized ED process flow for laboratory HIV testing, we compared time estimates for each process step across all EDs and selected the minimum time estimate required for each step. We calculated hypothetical optimized process costs per HIV test result using the fourth-generation HIV assay and equipment. We assumed that (1) personnel assigned to conduct each step and the materials used in the step were the same as those used by the hospital with the most efficient process for that step or (2) personnel assigned to conduct each step were the lowest-cost personnel involved in that step at any hospital, and materials used were the lowest-cost materials reported by any hospital.
RESULTS
Process flows and time estimates
We examined the type of HIV test, type of consent, and process flow for each hospital (Table 1) . Hospitals A, C, and D conducted POC HIV testing for fast-track ED patients and laboratory HIV testing for other ED patients; Hospital B conducted laboratory HIV testing for both fast-track and other ED patients. Hospitals A and B were using third-generation laboratory assays, and Hospitals C and D were using fourth-generation laboratory assays.
All hospitals obtained oral consent prior to collecting a specimen except Hospital B, which obtained written opt-out consent at registration. The process of providing information about HIV testing varied among hospitals. A separate information and consent step occurred at Hospital A, whereas Hospitals B, C, and D integrated information about HIV testing into the registration process. Confirmation of eligibility for HIV testing was automated using data from the electronic medical record (EMR) for all patients at Hospital B and for non-fast-track ED patients at Hospital A. At the remaining hospitals, obtaining eligibility information required manual review of paper records or requesting it orally from the patient. Similarly, hospitals differed based on whether the HIV test was ordered electronically or using a paper-based system, and in the types of personnel who ordered the test, collected the specimen, and processed the test (Table 1) . Processes for delivery of nonreactive results to patients also varied across hospitals. At Hospital A, counselors delivered nonreactive results to fast-track patients; other patients could obtain their nonreactive results from a call-in center. Hospital B provided nonreactive results as part of the ED discharge summary. In Hospital D, ED technicians delivered nonreactive results, and Hospital C did not actively deliver nonreactive results to ED patients on a routine basis. In contrast, all hospitals followed similar processes to deliver reactive results, conduct confirmatory HIV testing, and link patients to care, although the personnel who conducted these tasks and the confirmatory tests differed ( Table 1) .
We also estimated times to complete each process step. The process step was incorporated into the standard registration process or was automated with no additional labor time required, when no time estimate was indicated. The process of confirming screening eligibility at Hospital C, which the counselor conducted and which included an additional verification step to safeguard against unauthorized HIV screening, took substantially longer (13.0-16.0 minutes) than at the other hospitals (0.0-5.0 minutes). The time required to order tests and collect samples also varied by hospital, depending on the type and complexity of the ordering and documentation systems (e.g., manual vs. electronic) and whether samples were collected separately or during an existing blood draw. Documentation and delivery of nonreactive results by counselors at Hospital A in the fast track took 11.9 minutes, substantially longer than delivery of results by ED technicians at Hospital D (2.0 minutes), because counselors at Hospital A also required time to find and enter documentation in the paper chart, whereas results at Hospital D were automatically entered into the EMR ( Table 2 ).
All hospitals required substantial time for documentation and delivery of reactive test results (13.0-38.5 minutes) and linkage to care (18.0-26.0 minutes). Times for confirmatory testing varied widely depending on whether the confirmatory test was processed immediately in the laboratory on the initial specimen or on an additional blood sample obtained separately, and on whether the confirmatory test was conducted on-site or sent to an outside laboratory for processing ( Table 2) .
Costs for patients completing all testing steps
We calculated the labor and materials costs for each testing step in each ED and the estimated total cost per patient who completed the HIV testing process with either a nonreactive or reactive result ( (Table 3) .
Hypothetical optimized process cost
We created a hypothetical optimized process flow for non-fast-track patients using the minimum estimate required at each step across all EDs. Briefly, the optimized process flow for patients receiving nonreactive results was assumed to be: provision of information about HIV testing integrated into the registration process, HIV test ordered by registrar at registration (1 minute), automated verification of HIV screening eligibility by an EMR interface, blood collection by a phlebotomist at triage (1 minute), batching and loading blood samples by laboratory technician with automated barcode scanning (2 minutes), automated documentation, and delivery of nonreactive results as part of discharge instructions (Figure) .
We compared the labor and materials costs for each step and total costs per patient who completed the HIV laboratory testing process for the hypothetical optimized process flow with the labor and materials costs for each testing step in each ED and the estimated total cost per patient who completed the HIV testing process with either a nonreactive or reactive result. The cost of completing an HIV test with a nonreactive result using this hypothetical optimized process was $11.05 based on personnel and materials costs from the hospitals with the minimum process time for each step, which was approximately 45% lower than the median observed laboratory HIV testing cost. Substituting lowest-cost personnel and materials for the actual costs incurred in hospitals with the minimum process time did not substantially lower the cost (Table 4) .
For patients with reactive results, the hypothetical optimized process flow assumed that confirmatory testing was performed on-site and the experience at Public Health Reports / 2016 Supplement 1 / Volume 131 Table 2 . Estimated times for HIV testing process steps, by ED track, at four hospitals in the Bronx, New York, and Washington, D.C., observed during the period July 2013-September 2014 Hospital D, where medical providers reported spending 10 minutes delivering the results before introducing the patients to navigators for linkage to care. The hypothetical optimized process cost for patients receiving a reactive result was $82.61; the cost would be lowered to $72.19 if counselors, instead of medical providers, could deliver these results in 10 minutes. Because of the small number of reactive results reported by each hospital, however, the total cost savings from changes in the process for delivering reactive results would be small (Table 4 ).
Cost to conduct expanded HIV testing
The average number of ED admissions per month at the four hospitals ranged from approximately 3,500 to 6,000. The percentage of all ED admissions tested for HIV ranged from 5% to 16%, and the percentage of those with a reactive result ranged from 0.3% to 2.3%. The cost per ED visit to conduct POC and laboratory 
DISCUSSION
We conducted a micro-costing study in four hospitals participating in HPTN 065 that had switched from POC to rapid-result laboratory testing for some or all of their patients who received HIV screening in the ED. We found that after this switch, laboratory HIV The process step was incorporated into the standard registration process or was automated, and no additional labor cost was incurred. 25, 26 Laboratory testing has the potential for lower costs vs. POC testing due to batch processing; some laboratory tests have the potential for cost savings due to consumption of fewer controls. In this study, however, we did not observe consistent cost patterns across these testing modalities. This finding is likely due to substantial variation among the hospitals in testing volumes and HIV testing process flows. For example, we found in a sensitivity analysis that if hospitals increased their current testing volumes to 50% of all ED admissions, the cost to conduct HIV testing per ED visit would increase by $8.08
at a hospital using rapid-result laboratory testing or by $26.61 at a hospital where fast-track patients received POC testing using a relatively expensive process flow. We also found that an optimized process could achieve additional cost savings, but achieving these savings would require investments in electronic system interfaces to further automate testing processes. These investments require both time and resources; for example, a bioinformatics specialist at one hospital reported that a project to automate confirmation of HIV test eligibility was conducted in three phases during 10 months and required an estimated 316 hours of consultant programmer time and 64 hours of in-house project management time.
Limitations
Our analysis was subject to several limitations. We deliberately selected four hospitals that had successfully switched from POC to rapid-result laboratory testing for some or all of their ED patients. However, these hospitals are not representative of all 17 sites participating in the expanded HIV testing component of HPTN 065. Also, because the labor time estimates excluded downtime, and we were unable to include overhead costs, our estimates were lower than the total costs to the hospitals for conducting HIV testing and should not be extrapolated (e.g., to consider the adequacy of insurance reimbursement levels for these services). Downtime costs and some overhead costs were principally associated with labor costs, however, and in the hypothetical optimized process, flow automated processes replaced many labor costs. The estimated cost of the hypothetical optimized process, therefore, may more accurately reflect ultimate total hospital costs. Additionally, our cost estimates were based on current testing volumes at each hospital. At higher testing volumes, materials costs for laboratory testing would be lower because costs of controls, equipment, and service contracts would be amortized over a larger number of tests.
CONCLUSION
We found that costs of HIV testing varied widely among four hospitals that had successfully switched from POC to rapid-result laboratory HIV testing for expanded screening of ED patients. We estimated that using a hypothetical optimized process flow with automated steps could reduce costs by approximately 45% for patients with nonreactive results. These observations provide a basis for targeting efforts to optimize process flows and methods for estimating costs that, in EDs that screen patients for HIV, might be incorporated into negotiated agreements for fixed payments for ED services. In addition to ensuring appropriate reimbursement for HIV screening tests in the ED setting, policy makers and hospital leaders should seek financing for electronic system interfaces to further automate HIV testing processes.
